logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

John Chen

This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignee: Janssen Biotech, Inc.. Active years: 2015-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Chen. Retrieved from https://idiyas.com/inventor/john-chen-13yiv3r6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 3

Forward Citations = 36(Granted Patents)


Company Filing History:

goldMedal5 out of 433 
 
Janssen Biotech, Inc.
 patents

Years Active: 2015-2023

Loading Chart...
5 patents (USPTO):Explore Patents
1. 11732050 - Neutralizing human anti-CD27 antibodies (2023-08-22),
2. 10689453 - Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies (2020-06-23),
3. 10301392 - Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies (2019-05-28),
4. 9683046 - Nucleic acid molecules encoding anti-CD27 antibodies (2017-06-20),
5. 9102737 - Human anti-CD27 antibodies, methods and uses (2015-08-11),

Title: Innovations by John Chen in Immunotherapy

Introduction

John Chen is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of immunotherapy. With a total of five patents to his name, Chen has focused on developing human antibodies that target CD27, a crucial component in immune response regulation.

Latest Patents

Chen's latest patents include groundbreaking work on neutralizing human anti-CD27 antibodies. These antibodies are designed to block the binding of CD27 to its ligand CD70, effectively neutralizing the bioactivity of CD27. This innovation has implications for T-cell proliferation, B-cell differentiation, and the overall immune response. Additionally, his methods for inhibiting naive T-cell proliferation using anti-CD27 antibodies further enhance the potential for diagnosing and treating diseases associated with CD27 activity.

Career Highlights

John Chen is currently employed at Janssen Biotech, Inc., where he continues to advance his research in immunotherapy. His work has garnered attention for its potential to improve treatment options for various diseases linked to immune system dysfunction.

Collaborations

Chen collaborates with notable colleagues, including Johan Fransson and Natalie Fursov, who contribute to the innovative research environment at Janssen Biotech.

Conclusion

John Chen's contributions to immunotherapy through his patents on anti-CD27 antibodies represent a significant advancement in the field. His work not only enhances our understanding of immune responses but also opens new avenues for therapeutic interventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…